ScreenerHero

ABUS Arbutus Biopharma Corporation

NAS · US · Healthcare · Biotechnology · arbutusbio.com
4.290USD-4.24%Mkt Cap: 657.55M $P/E: 5.43

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conj…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap657.55M USD
Enterprise Value797.36M USD
Revenue (TTM)181.72M USD
Gross Profit163.92M USD
Net Income (TTM)-33.50M USD
Revenue/Share0.94 USD
Last Price4.290 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)5.43
P/E (Forward)-27.10
PEG—
EV/EBITDA5.41
EV/Revenue4.39
P/S3.78
P/B3.42
EPS (TTM)0.76
EPS (Forward)-0.17
52W Range
3.50041% of range5.448
52W High5.448 USD
52W Low3.500 USD
Profitability
Gross Margin90.20%
Oper. Margin-567.16%
EBITDA Margin81.15%
Profit Margin-237.88%
ROE-43.75%
ROA-35.41%
Growth
Revenue Growth-90.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.64M USD
CapEx (TTM)—
FCF Margin-44.15%
FCF Yield-12.20%
Net Debt-89.00M USD
Net Debt/EBITDA-0.60
Balance Sheet
Debt/Equity0.01
Current Ratio81.42
Quick Ratio81.08
Book Value/Sh1.31 USD
Cash/Share0.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateNov 4, 2010
Analyst Consensus
Rating—
Target (Mean)5.367 USD
Upside (mean)+25.1%
Target Range5.367 USD – 5.367 USD
# Analysts1
Ownership
Shares Out.153.28M
Float122.36M
Insiders20.42%
Institutions72.45%
Short Interest
Short Ratio3.7d
Short % Float13.86%
Short % Out.9.33%
Shares Short18.48M
Short (prev mo.)18.46M
Technical
SMA 504.840 (-11.4%)
SMA 2004.538 (-5.5%)
Beta0.76
S&P 52W Chg16.45%
Avg Vol (30d)7.64M
Avg Vol (10d)11.96M
Technical Indicators
RSI (14)31.8
MACD-0.1137
MACD Signal-0.0389
MACD Hist.-0.0748
BB Upper5.383 USD
BB Middle4.858 USD
BB Lower4.333 USD
BB Width21.62%
ATR (14)0.1813 USD
Vol Ratio (20d)0.58x